ABMD News and Press, ABIOMED Inc. From 10/28/21

Image source: The Motley Fool. ABIOMED, inc (NASDAQ: ABMD) Q2 2022 Earnings Call Oct 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: ABIOMED, inc (ABMD) Q2 2022 Earnings Call Transcript

Abiomed, Inc. (ABMD) Q2 2022 Earnings Conference Call October 28, 2021 8:00 AM ET Company Participants Nicole Nath – Manager, Investor Relations Mike Minogue – Chairman, President and Chief Executive Officer Todd Trapp – Vice President and Chief Financial Officer Conferen...

Abiomed shares fall (ABMD -4.7%) after the company posted third-quarter revenue that was in line with Wall Street estimates. The company's quarterly revenue increased 18% to $248.1M, in line with analysts' average estimate, helped by the performance of its Impella heart pump business. Worldwi...

Abiomed (NASDAQ:ABMD): Q3 Non-GAAP EPS of $1.03 beats by $0.03; GAAP EPS of $1.24 beats by $0.22. Revenue of $248.1M (+18.3% Y/Y) in-line. Press Release Worldwide Impella® heart pump product revenue for the quarter totaled $235.8 million, an increase of 18% compared to $199.7 million dur...

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021. Q2 financial summary and operational highlights: Revenue for the quarter totaled $248.1 million, an incre...

The medical devices industry is rebounding from its pandemic-led decline in demand with the rescheduling of elective surgeries and the increasing need for services by an aging population. Continuing innovations and the integration of advanced technologies positions the industry well for growt...

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, October 28, 2021 at 8:00 a.m. ET. Michae...

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around t...

My actively managed Roth IRA portfolio (30 CEFs and 26 REITs for income, and 132 stocks for swing trading mostly S&P 500 stocks) continues to realize profits. In August, I closed 12 stock trades for a net gain, including dividends, of +41.5% (mean) or +38.2% (cost-weighted), for a...

The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed ’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP’s regulatory review processes inc...